Morphea is a chronic inflammatory disease characterised by localised fibrosis of the skin and subcutaneous tissues. Unlike systemic sclerosis it does not involve internal organs, but it can cause significant cosmetic and functional problems. As of 2026, important advances have been recorded in treatment approaches.
What Is Morphea?
Morphea, or localised scleroderma, is a connective tissue disease characterised by hardening and thickening of the skin resulting from excessive collagen deposition. The disease can occur at any age but most commonly presents in women between the ages of 20 and 50. The female-to-male ratio is approximately 3:1.
In the pathogenesis, vascular damage, immune activation, and fibroblast dysregulation stand out as three key mechanisms. Genetic predisposition and environmental factors such as infectious agents, trauma, and radiation can trigger the disease.
Types of Morphea
Plaque Morphea
This is the most common type and accounts for approximately sixty percent of all morphea cases. It presents as oval or round, firm, ivory-coloured plaques. During the active phase, a purple ring (lilac ring) surrounds the lesions, which is an indicator of inflammatory activity.
Linear Morphea
This is the most common type in childhood. It presents as fibrotic bands with a linear distribution along the extremities. Linear morphea affecting the forehead and scalp is termed "en coup de sabre." This form can lead to involvement of deep tissue and bone, causing growth asymmetries.
Generalised Morphea
Generalised morphea is diagnosed when four or more plaques are present in multiple body regions, or when lesions involve two or more anatomical areas. This form tends to follow a more aggressive course.
Deep Morphea
Deep morphea is a rare form that involves subcutaneous tissue and fascia. It is characterised by marked depression and tissue loss in the skin. Deep firmness is felt on palpation and it can lead to restricted movement.
Diagnostic Methods
Diagnosis is primarily based on clinical evaluation. The lilac ring in active lesions, ivory-coloured centre, and skin firmness are typical findings. Skin biopsy is the most reliable method to confirm the diagnosis. Histopathological examination reveals collagen thickening in the dermis, inflammatory cell infiltration, and entrapment of eccrine sweat glands within fibrosis.
Magnetic resonance imaging is used to evaluate the depth and extent of involvement, particularly in deep morphea and linear morphea cases. Ultrasound elastography can measure skin thickness and firmness, and is useful in monitoring response to treatment.
Current Treatment Approaches 2026
Topical Treatments
In limited plaque morphea, high-potency topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus) are preferred as first-line treatment. Topical vitamin D analogues can also be added to therapy to help reduce fibrosis.
Phototherapy
UVA1 phototherapy holds an important place in the treatment of morphea. Medium- and high-dose UVA1 radiation reduces fibrosis by stimulating dermal collagenases. Narrowband UVB treatment can also be used as an alternative.
Systemic Treatments
In widespread or rapidly progressive morphea, methotrexate is used alone or in combination with short-term systemic corticosteroids. Mycophenolate mofetil is an effective alternative in resistant cases. Current studies on JAK inhibitors are yielding promising results.
Physical Therapy
Physical therapy programmes are of great importance, particularly in linear morphea, to maintain joint range of motion and prevent the development of contractures.
Conclusion
Early intervention in morphea treatment is critical for halting disease progression and preventing functional losses. The evolving treatment options available in 2026 significantly improve patients' quality of life. Please contact us for pricing and to arrange a comprehensive dermatological evaluation at Virtuana Clinic.
References
- Fett N, Werth VP. "Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis." J Am Acad Dermatol. 2011;64(2):217–228. [PubMed]
- Fett N, Werth VP. "Update on morphea: part II. Outcome measures and treatment." J Am Acad Dermatol. 2011;64(2):231–242. [PubMed]
- DermNet NZ — Morphea. [DermNet]
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.